You are here: Industry Insights > Lung Cancer

News List

With the transaction exceeding 300 million US dollars reached, how is the exploration of Chinese inhibitor KRAS G12C? PharmaSources/Yefenghong
September 14, 2021
On September 2, Innovent announced that it had reached a global exclusive licensing agreement with Genfleet. Innovent, as an exclusive partner of Genfleet, will obtain the right to develop and commercialize GFH925...
Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer PR Newswire
January 21, 2025
Innovent and ASK Pharm jointly announce NMPA's approval of limertinib for treating lung cancer, with efficacy and safety proven and first - line treatment review ongoing.
Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration PRNewswire
December 20, 2024
Innovent Biologics announced that China's National Medical Products Administration (NMPA) has approved a New Drug Application (NDA) of DOVBLERON ® .
You Don't Have to Smoke to Get Lung Cancer drugs.com
January 22, 2022
Tobacco use is far and away the leading cause of lung cancer, but non-smokers are also at risk, experts say.
Air of optimism surrounds lung cancer vaccine pharmatimes
January 18, 2022
Cancer Research UK announces clinical trial for most common type of lung cancer
NICE approves lung cancer combination drug therapy for NHS use Pharmaceutical-Technology
January 14, 2022
People treated with pembrolizumab lived for 17.1 months on average versus 11.6 months for chemotherapy, trial data showed.
You Don't Have to Be a Smoker to Get Lung Cancer drugs.com
January 14, 2022
Think you're safe from lung cancer because you've never smoked? Think again.
Progress on Lung Cancer Drives Overall Decline in U.S. Cancer Deaths drugs.com
January 12, 2022
A new report offers hope on the lung cancer front: Patients are being diagnosed at an earlier stage in their disease and living longer due to better access to care, higher screening rates and improved treatments.
NICE recommends MSD’s Keytruda in combination with chemotherapy for routine treatment of lung cancer pharmatimes
January 07, 2022
With over 48,000 new cases diagnosed per year, lung cancer is the third most common cancer in the UK.
NICE recommends osimertinib for non-small cell lung cancer (NSCLC) EuropeanPharmaceuticalReview
December 02, 2021
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending osimertinib within the Cancer Drugs Fund (CDF).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page